Weizmann Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: October 29, 2025, 7:55 am

Competitors of Weizmann Ltd

All Competitor Stocks of Weizmann Ltd

Quarterly Result

Last Updated: August 20, 2025, 1:15 am

Below is a detailed analysis of the quarterly data for Weizmann Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

• For Sales, as of Jun 2025, the value is 29.99 Cr.. The value appears to be declining and may need further review. It has decreased from 36.25 Cr. (Mar 2025) to 29.99 Cr., marking a decrease of 6.26 Cr..
• For Expenses, as of Jun 2025, the value is 26.60 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 31.20 Cr. (Mar 2025) to 26.60 Cr., marking a decrease of 4.60 Cr..
• For Operating Profit, as of Jun 2025, the value is 3.39 Cr.. The value appears to be declining and may need further review. It has decreased from 5.05 Cr. (Mar 2025) to 3.39 Cr., marking a decrease of 1.66 Cr..
• For OPM %, as of Jun 2025, the value is 11.30%. The value appears to be declining and may need further review. It has decreased from 13.93% (Mar 2025) to 11.30%, marking a decrease of 2.63%.
• For Other Income, as of Jun 2025, the value is 0.04 Cr.. The value appears to be declining and may need further review. It has decreased from 0.06 Cr. (Mar 2025) to 0.04 Cr., marking a decrease of 0.02 Cr..
• For Interest, as of Jun 2025, the value is 0.21 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.23 Cr. (Mar 2025) to 0.21 Cr., marking a decrease of 0.02 Cr..
• For Depreciation, as of Jun 2025, the value is 1.08 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 1.37 Cr. (Mar 2025) to 1.08 Cr., marking a decrease of 0.29 Cr..
• For Profit before tax, as of Jun 2025, the value is 2.14 Cr.. The value appears to be declining and may need further review. It has decreased from 3.51 Cr. (Mar 2025) to 2.14 Cr., marking a decrease of 1.37 Cr..
• For Tax %, as of Jun 2025, the value is 25.23%. The value appears to be improving (decreasing) as expected. It has decreased from 33.90% (Mar 2025) to 25.23%, marking a decrease of 8.67%.
• For Net Profit, as of Jun 2025, the value is 1.20 Cr.. The value appears strong and on an upward trend. It has increased from -8.68 Cr. (Mar 2025) to 1.20 Cr., marking an increase of 9.88 Cr..
• For EPS in Rs, as of Jun 2025, the value is 0.76. The value appears strong and on an upward trend. It has increased from -5.47 (Mar 2025) to 0.76, marking an increase of 6.23.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Profit & Loss - Annual Report

Last Updated: October 15, 2025, 4:08 am

Growth

Last Updated: September 5, 2025, 1:56 pm

Balance Sheet

Last Updated: July 25, 2025, 2:04 pm

Below is a detailed analysis of the balance sheet data for Weizmann Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

• For Equity Capital, as of Mar 2025, the value is 15.00 Cr.. The value appears to be declining and may need further review. It has decreased from 16.00 Cr. (Mar 2024) to 15.00 Cr., marking a decrease of 1.00 Cr..
• For Reserves, as of Mar 2025, the value is 45.00 Cr.. The value appears to be declining and may need further review. It has decreased from 57.00 Cr. (Mar 2024) to 45.00 Cr., marking a decrease of 12.00 Cr..
• For Borrowings, as of Mar 2025, the value is 11.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 8.00 Cr. (Mar 2024) to 11.00 Cr., marking an increase of 3.00 Cr..
• For Other Liabilities, as of Mar 2025, the value is 19.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 17.00 Cr. (Mar 2024) to 19.00 Cr., marking an increase of 2.00 Cr..
• For Total Liabilities, as of Mar 2025, the value is 91.00 Cr.. The value appears to be improving (decreasing). It has decreased from 97.00 Cr. (Mar 2024) to 91.00 Cr., marking a decrease of 6.00 Cr..
• For Fixed Assets, as of Mar 2025, the value is 33.00 Cr.. The value appears strong and on an upward trend. It has increased from 26.00 Cr. (Mar 2024) to 33.00 Cr., marking an increase of 7.00 Cr..
• For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 1.00 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 1.00 Cr..
• For Investments, as of Mar 2025, the value is 22.00 Cr.. The value appears to be declining and may need further review. It has decreased from 35.00 Cr. (Mar 2024) to 22.00 Cr., marking a decrease of 13.00 Cr..
• For Other Assets, as of Mar 2025, the value is 35.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 35.00 Cr..
• For Total Assets, as of Mar 2025, the value is 91.00 Cr.. The value appears to be declining and may need further review. It has decreased from 97.00 Cr. (Mar 2024) to 91.00 Cr., marking a decrease of 6.00 Cr..

Notably, the Reserves (45.00 Cr.) exceed the Borrowings (11.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Free Cash Flow

Financial Efficiency Indicators

Share Holding Pattern

Key Financial Ratios

After reviewing the key financial ratios for Weizmann Ltd, here is a detailed analysis based on the latest available data and recent trends:

• For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
• For Basic EPS (Rs.), as of Mar 25, the value is -2.32. This value is below the healthy minimum of 5. It has decreased from 5.65 (Mar 24) to -2.32, marking a decrease of 7.97.
• For Diluted EPS (Rs.), as of Mar 25, the value is -2.30. This value is below the healthy minimum of 5. It has decreased from 5.65 (Mar 24) to -2.30, marking a decrease of 7.95.
• For Cash EPS (Rs.), as of Mar 25, the value is 7.34. This value is within the healthy range. It has decreased from 7.76 (Mar 24) to 7.34, marking a decrease of 0.42.
• For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 39.28. It has decreased from 45.90 (Mar 24) to 39.28, marking a decrease of 6.62.
• For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 39.28. It has decreased from 45.90 (Mar 24) to 39.28, marking a decrease of 6.62.
• For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 75.67. It has decreased from 77.50 (Mar 24) to 75.67, marking a decrease of 1.83.
• For PBDIT / Share (Rs.), as of Mar 25, the value is 9.95. This value is within the healthy range. It has increased from 9.66 (Mar 24) to 9.95, marking an increase of 0.29.
• For PBIT / Share (Rs.), as of Mar 25, the value is 7.77. This value is within the healthy range. It has decreased from 7.94 (Mar 24) to 7.77, marking a decrease of 0.17.
• For PBT / Share (Rs.), as of Mar 25, the value is 7.24. This value is within the healthy range. It has decreased from 7.53 (Mar 24) to 7.24, marking a decrease of 0.29.
• For Net Profit / Share (Rs.), as of Mar 25, the value is 5.17. This value is within the healthy range. It has decreased from 6.04 (Mar 24) to 5.17, marking a decrease of 0.87.
• For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -2.32. This value is below the healthy minimum of 2. It has decreased from 5.65 (Mar 24) to -2.32, marking a decrease of 7.97.
• For PBDIT Margin (%), as of Mar 25, the value is 13.14. This value is within the healthy range. It has increased from 12.46 (Mar 24) to 13.14, marking an increase of 0.68.
• For PBIT Margin (%), as of Mar 25, the value is 10.27. This value is within the healthy range. It has increased from 10.24 (Mar 24) to 10.27, marking an increase of 0.03.
• For PBT Margin (%), as of Mar 25, the value is 9.56. This value is below the healthy minimum of 10. It has decreased from 9.71 (Mar 24) to 9.56, marking a decrease of 0.15.
• For Net Profit Margin (%), as of Mar 25, the value is 6.83. This value is within the healthy range. It has decreased from 7.79 (Mar 24) to 6.83, marking a decrease of 0.96.
• For NP After MI And SOA Margin (%), as of Mar 25, the value is -3.06. This value is below the healthy minimum of 8. It has decreased from 7.29 (Mar 24) to -3.06, marking a decrease of 10.35.
• For Return on Networth / Equity (%), as of Mar 25, the value is -5.90. This value is below the healthy minimum of 15. It has decreased from 12.30 (Mar 24) to -5.90, marking a decrease of 18.20.
• For Return on Capital Employeed (%), as of Mar 25, the value is 18.91. This value is within the healthy range. It has increased from 16.83 (Mar 24) to 18.91, marking an increase of 2.08.
• For Return On Assets (%), as of Mar 25, the value is -3.96. This value is below the healthy minimum of 5. It has decreased from 9.21 (Mar 24) to -3.96, marking a decrease of 13.17.
• For Long Term Debt / Equity (X), as of Mar 25, the value is 0.01. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.01, marking an increase of 0.01.
• For Total Debt / Equity (X), as of Mar 25, the value is 0.15. This value is within the healthy range. It has increased from 0.10 (Mar 24) to 0.15, marking an increase of 0.05.
• For Asset Turnover Ratio (%), as of Mar 25, the value is 1.25. It has increased from 1.24 (Mar 24) to 1.25, marking an increase of 0.01.
• For Current Ratio (X), as of Mar 25, the value is 0.95. This value is below the healthy minimum of 1.5. It has decreased from 1.02 (Mar 24) to 0.95, marking a decrease of 0.07.
• For Quick Ratio (X), as of Mar 25, the value is 0.64. This value is below the healthy minimum of 1. It has increased from 0.58 (Mar 24) to 0.64, marking an increase of 0.06.
• For Inventory Turnover Ratio (X), as of Mar 25, the value is 12.83. This value exceeds the healthy maximum of 8. It has increased from 4.55 (Mar 24) to 12.83, marking an increase of 8.28.
• For Dividend Payout Ratio (NP) (%), as of Mar 25, the value is -22.05. This value is below the healthy minimum of 20. It has decreased from 8.84 (Mar 24) to -22.05, marking a decrease of 30.89.
• For Dividend Payout Ratio (CP) (%), as of Mar 25, the value is -346.43. This value is below the healthy minimum of 20. It has decreased from 6.78 (Mar 24) to -346.43, marking a decrease of 353.21.
• For Earning Retention Ratio (%), as of Mar 25, the value is 122.05. This value exceeds the healthy maximum of 70. It has increased from 91.16 (Mar 24) to 122.05, marking an increase of 30.89.
• For Cash Earning Retention Ratio (%), as of Mar 25, the value is 446.43. This value exceeds the healthy maximum of 70. It has increased from 93.22 (Mar 24) to 446.43, marking an increase of 353.21.
• For Interest Coverage Ratio (X), as of Mar 25, the value is 18.51. This value is within the healthy range. It has decreased from 23.49 (Mar 24) to 18.51, marking a decrease of 4.98.
• For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 10.62. This value is within the healthy range. It has decreased from 15.68 (Mar 24) to 10.62, marking a decrease of 5.06.
• For Enterprise Value (Cr.), as of Mar 25, the value is 174.57. It has decreased from 182.48 (Mar 24) to 174.57, marking a decrease of 7.91.
• For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.49. This value is within the healthy range. It has increased from 1.48 (Mar 24) to 1.49, marking an increase of 0.01.
• For EV / EBITDA (X), as of Mar 25, the value is 11.33. This value is within the healthy range. It has decreased from 11.91 (Mar 24) to 11.33, marking a decrease of 0.58.
• For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.41. This value is within the healthy range. It has decreased from 1.43 (Mar 24) to 1.41, marking a decrease of 0.02.
• For Retention Ratios (%), as of Mar 25, the value is 122.05. This value exceeds the healthy maximum of 70. It has increased from 91.15 (Mar 24) to 122.05, marking an increase of 30.90.
• For Price / BV (X), as of Mar 25, the value is 2.73. This value is within the healthy range. It has increased from 2.42 (Mar 24) to 2.73, marking an increase of 0.31.
• For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.41. This value is within the healthy range. It has decreased from 1.43 (Mar 24) to 1.41, marking a decrease of 0.02.
• For EarningsYield, as of Mar 25, the value is -0.02. This value is below the healthy minimum of 5. It has decreased from 0.05 (Mar 24) to -0.02, marking a decrease of 0.07.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Fair Value

*Investments are subject to market risks

Strength and Weakness